factual
Myeloma treatment doubled patient survival
New myeloma drugs like Revlimid and Velcade have roughly doubled survival, turning a disease where patients lived an average of 3-4 years into one where patients can expect to live 7-10 years longer.
factualpending
Speaker
Vincent RajkumarEvidence Quote
“these drugs are great because they have doubled the survival”
Created: 6/13/2026, 12:13:30 AM
Your notes
Loading notes...